Institutional members access full text with Ovid®

Share this article on:

SYMPTOMATIC THERAPY OF MULTIPLE SCLEROSIS

Markowitz, Clyde

doi: 10.1212/01.CON.0000389936.61789.04
Article

Despite the important advances being made in disease-modifying multiple sclerosis (MS) therapies, patients are often affected by a wide variety of symptoms caused by neurologic injury in MS. Common symptoms that patients with MS experience during the course of their illness include weakness, ambulatory impairment, sensory disturbances that may be unpleasant or even painful, ataxia and tremor, bladder and bowel dysfunction, sexual dysfunction, fatigue, spasticity, vertigo, depression and other psychiatric symptoms, cognitive impairment, and paroxysmal symptoms such as cramps, spasms, Lhermitte symptom, and Uhthoff phenomenon. These MS symptoms can cause loss of vocation and social isolation. Neurologic care of patients with MS often involves a greater degree of management of the symptoms caused by MS than appropriate prescription of disease-modifying treatments. In addition, many of the disease-modifying therapies have unpleasant side effects that may also require treatment. This article will focus on medical treatments, use of rehabilitation medicine, and, in select cases, surgical interventions for management of MS symptoms.

Note: Text referenced in the Quintessentials Preferred Responses, which appear later in this issue, is indicated in yellow shading throughout this article.

Relationship Disclosure: Dr Markowitz has received personal compensation for consulting activities from Bayer; Biogen Idec; EMD Serono, Inc.; Novartis; Teva Neuroscience; and Wyeth. Dr Markowitz has received research support from Bayer; Biogen Idec; BioMS Medical Corporation; EMD Serono, Inc.; Novartis; and Teva Neuroscience. Dr Markowitz's compensation and/or research work has been funded entirely or in part by a grant to his university from a pharmaceutical or device company. The grant agreement requires that the name of the funding entity and the purpose of the grant may not be disclosed.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Markowitz has nothing to disclose.

© 2010 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website